These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
3. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
4. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK Front Immunol; 2021; 12():793953. PubMed ID: 34899762 [TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
6. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387 [TBL] [Abstract][Full Text] [Related]
7. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202 [TBL] [Abstract][Full Text] [Related]
10. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
11. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion. Xue S; Han Y; Wu F; Wang Q Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19. Dakal TC Immunobiology; 2021 Jan; 226(1):152021. PubMed ID: 33232865 [TBL] [Abstract][Full Text] [Related]
14. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189 [TBL] [Abstract][Full Text] [Related]
15. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
16. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
17. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519 [TBL] [Abstract][Full Text] [Related]
18. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
19. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630 [No Abstract] [Full Text] [Related]
20. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]